World Pharma News / Published News

Drug Injury Watch: History Of Singulair And Psychiatric Adverse Reactions In Canada: 1997 - January 2009

tjlpa — Wed, 15 Jul 2009 10:07:25 EEST

July 2009 Canadian Adverse Reaction Newsletter Provides Summary Of Reports Made To Health Canada

1 Vote(s)

5-year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus Compared to NPH

PharmaNewsEU — Tue, 14 Jul 2009 22:12:49 EEST

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has announced that the results of the long-term, 5-year study of Lantus® (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopa

1 Vote(s)

WHO grants prequalification to Cervarix: GSK's vaccine to help combat cervical cancer in developing nations

PharmaNewsEU — Tue, 14 Jul 2009 22:12:32 EEST

The World Health Organization (WHO) has awarded prequalification to Cervarix®, GlaxoSmithKline's cervical cancer vaccine. The WHO decision is necessary for UN agencies and the GAVI Alliance to purch

1 Vote(s)

New Online Resource Launches For Patients With Chronic Myeloid Leukemia

god — Tue, 14 Jul 2009 22:12:15 EEST

Many people living with cancer are researching their illnesses online. In fact, research has shown that patients who use the Internet consider it a more useful source of information as compared with

1 Vote(s)

Bayer acquires exclusive rights to Bioton's insulin SciLin

worldpharmanews — Mon, 13 Jul 2009 10:09:16 EEST

Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton's Singaporean subsidiary, SciGen, to strengthen i

2 Vote(s)

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial

worldpharmanews — Sun, 12 Jul 2009 01:58:02 EEST

Amgen (Nasdaq: AMGN) announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced

2 Vote(s)

AstraZeneca to Advance AZD3480 in ADHD

worldpharmanews — Fri, 10 Jul 2009 10:11:02 EEST

AstraZeneca plans to conduct further development of AZD3480 by initiating Phase IIb studies in attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment t

2 Vote(s)

Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US

worldpharmanews — Fri, 10 Jul 2009 10:10:48 EEST

Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new estradiol-based oral contraceptive (estradiol valerate/dienogest). It seeks approval for the

2 Vote(s)

Study sheds light on vitamin D's anti-cancer properties

PharmaNewsEU — Fri, 10 Jul 2009 09:58:56 EEST

A new EU-funded study increases our understanding of vitamin D's apparent anti-cancer properties. The findings support the need for further clinical trials examining the potential of the active form

1 Vote(s)

European Commission approves statement on lipid improvement for Viramune label

PharmaNewsEU — Thu, 09 Jul 2009 00:12:10 EEST

Boehringer Ingelheim announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for Viramune® (nevirapine) in the treatment of patients with HIV. T

1 Vote(s)

EU-funded study reveals schizophrenia triggers

PharmaNewsEU — Thu, 09 Jul 2009 00:11:59 EEST

An international team of researchers has pieced together the puzzle of the genetics of schizophrenia. Published in the journal Nature, their findings bring to light a number of new 'common single-le

2 Vote(s)

FDA Takes Actions on Darvon, Other Pain Medications Containing Propoxyphene

worldpharmanews — Thu, 09 Jul 2009 00:04:59 EEST

The U.S. Food and Drug Administration is taking several actions to reduce the risk of overdose in patients using pain medications such as Darvon and Darvocet that contain propoxyphene. The actions we

2 Vote(s)

Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies

worldpharmanews — Wed, 08 Jul 2009 10:15:27 EEST

Through the acquisition of the Aarhus-based biotech company NeuronIcon, Lundbeck will gain ownership of technologies that may lead to a breakthrough in the treatment of brain damage following strokes

2 Vote(s)

Top 10 Tips for Staying Healthy When Money is Tight

worldpharmanews — Wed, 08 Jul 2009 10:07:44 EEST

Several area health care organizations agree that today's tough economic times can make staying healthy a challenge. The organizations provided tips for Ohioans to stay healthy. Those organizations

1 Vote(s)

Drug Injury Watch: Popular Asthma Medicine Singulair Associated With Psychiatric Disorders In Children

tjlpa — Tue, 07 Jul 2009 00:07:46 EEST

New Medical Journal Article Follows June 2009 FDA-Required Warning For Singulair About Neuropsychiatric Events

2 Vote(s)

Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer

worldpharmanews — Tue, 07 Jul 2009 00:07:33 EEST

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) have entered into an Acquisition and License Agreement by which Graceway will acquire the wo

2 Vote(s)

Lu AA24530 shows positive results in major depressive disorder phase II study

worldpharmanews — Sun, 05 Jul 2009 02:17:51 EEST

H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).

2 Vote(s)

Why Drugs Dona4t Work as They Should

eva — Sun, 05 Jul 2009 02:17:40 EEST

The average US adult is now regularly taking more than two prescription drugs at any given time. While pharmaceuticals continue to develop ever more elegant drugs, however, there is increasing concer

1 Vote(s)

OpSec Security Identifies Alarming Trends in Illicit Bulk Pharmaceuticals and Drugs Online

kfailla — Sun, 05 Jul 2009 02:16:45 EEST

This two-year study assesses the increasing risks in counterfeiting pharmaceuticals in the online marketplace.

1 Vote(s)

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

worldpharmanews — Sat, 04 Jul 2009 16:19:14 EEST

Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follic

2 Vote(s)

Pharmaceutical and Healthcare Market in Poland 2009

pmrcorporate — Fri, 03 Jul 2009 10:53:21 EEST

In 2008 the pharmacy market in Poland was worth PLN 24.1bn (€6.9bn), which represented 11.5% growth in comparison with 2007. At present, it is one of the areas of the Polish economy which boasts the

2 Vote(s)

Drug Injury Watch: Smoking Cessation Drugs Chantix, Wellbutrin, And Zyban Are Getting New

tjlpa — Fri, 03 Jul 2009 10:50:37 EEST

Will Warn About Risk Of Serious Neuropsychiatric Symptoms Including Agitation, Depression, Suicidal Thoughts, And Attempted Suicide

2 Vote(s)

Drug Injury Watch: Brandname Accutane Acne Medicine Is Being Removed From U.S. Market By Roche

tjlpa — Fri, 03 Jul 2009 10:50:16 EEST

Accutane Recall Due To Safety Issues Or Declining Sales Or Lawsuit Losses Or Some Combination Of These Factors?

1 Vote(s)

European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines

PharmaNewsEU — Fri, 03 Jul 2009 10:49:50 EEST

Finalising a review of the safety and efficacy of dextropropoxyphene-containing medicines, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that their r

2 Vote(s)

ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes

PharmaNewsEU — Tue, 30 Jun 2009 21:46:09 EEST

AstraZeneca and Bristol-Myers Squibb Company today announced that their marketing authorisation application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Prod

2 Vote(s)

Lundbeck receives FDA Complete Response Letter on Serdolect for the treatment of schizophrenia

worldpharmanews — Sun, 28 Jun 2009 01:14:18 EEST

H. Lundbeck A/S (LUN.CO; LUN DC) has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Serdolect® (sertindole) for the treatment of schizophrenia.

2 Vote(s)

Drug Injury Watch: Generic Drug Maker Caraco Fails To Correct Manufacturing Problems First Discovered In May 2008

tjlpa — Fri, 26 Jun 2009 23:53:17 EEST

FDA And U.S. Marshals Seize Drug Products From Caraco's Three Michigan Facilities Due To Continuing Lack Of Quality Controls

3 Vote(s)

Obama Negotiates Reduction of Prescription Drug Costs

eva — Fri, 26 Jun 2009 23:52:56 EEST

When people discuss the ever-rising costs of health care, one of the most common complaints is the sometimes exorbitant price of prescription medicines.

1 Vote(s)

European Medicines Agency launches public consultation on new transparency policy

PharmaNewsEU — Fri, 26 Jun 2009 00:30:32 EEST

The European Medicines Agency is inviting comments on its draft transparency policy until 25 September 2009. Since its inauguration in 1995, the Agency has worked continuously to improve the transpar

2 Vote(s)

Sutent Significantly Improved Progression-Free Survival

worldpharmanews — Fri, 26 Jun 2009 00:25:15 EEST

Pfizer has announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which

2 Vote(s)

Drug Injury Watch: Merck's Popular Asthma Drug Singulair Associated With Suicide And Depression

tjlpa — Thu, 25 Jun 2009 00:08:58 EEST

FDA Has Gone From "No Link" In January 2009 To Wanting An Increased Warning About These Neuropsychiatric Events In June 2009

3 Vote(s)

Drug Injury Watch: Gardasil Vaccine Associated With 28 Deaths In 2008 According To Judicial Watch Report

tjlpa — Thu, 25 Jun 2009 00:08:47 EEST

This Public Interest Group Reviewed Gardasil Cases Found In FDA's Vaccine Adverse Event Reporting System (VAERS)

3 Vote(s)

World Pharmaceutical (China) Summit 2009 will be held in Shanghai

anitameng — Thu, 25 Jun 2009 00:08:38 EEST

World Pharmaceutical (China) Summit 2009 is one of the major international functions that link pharma executives from all over the world together.

2 Vote(s)

Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission

PharmaNewsEU — Tue, 23 Jun 2009 00:09:57 EEST

Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®. This new O

2 Vote(s)

My Health: What Are Superfoods? Top 10 Facts (and Myths)

healthylivinggal — Sat, 20 Jun 2009 14:43:25 EEST

Here are the top ten facts and myths about super foods.

2 Vote(s)

New zebrafish model offers new insights into skin cancer

PharmaNewsEU — Sat, 20 Jun 2009 14:35:52 EEST

Scientists in the UK and Switzerland have identified a signalling pathway, PI3K (phosphoinositide 3-kinase) that shows promise as a target for treating aggressive skin cancer. Their results, based on

1 Vote(s)

Drug Injury Watch: Relatively Little Is Known About Long-Term Safety Of Bisphosphonates Such As Fosamax, Boniva, Actonel

tjlpa — Sat, 20 Jun 2009 01:12:22 EEST

Doctors Should Inform Their Patients About Potential Serious Side Effects Like Osteonecrosis Of The Jaw And Femur Fractures

2 Vote(s)

Drug Injury Watch: June 18 Congressional Subcommittee Meeting About Medical Device Safety Act of 2009

tjlpa — Thu, 18 Jun 2009 00:04:06 EEST

This Bill, If Passed, Would Restore An Injured Patient's Right To Sue A Medical Device Manufacturer By Reversing Riegel v. Medtronic Ruling

2 Vote(s)

Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration

PharmaNewsEU — Thu, 18 Jun 2009 00:03:52 EEST

Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for th

2 Vote(s)

Drug Injury Watch: Medication Errors Are One Of The Most Common Medical Mistakes, But Number Can Be Reduced

tjlpa — Wed, 17 Jun 2009 02:49:11 EEST

Two Reports From April 2009 Medical Journal Offer Possible Solutions To A Problem Which Affects At Least 1.5 Million People Per Year

2 Vote(s)